Stacey Johnson
Stacey Johnson is the editor of Signals and a contributor. For 25 years, Stacey has been providing strategic communications counsel to government, corporate, technology and health organizations. She began her career at the CTV Television Network and then moved to Hill & Knowlton Canada where she advised clients in a variety of industries and sectors. Stacey is the Vice President, Communications and Marketing for CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies. She has a Master's degree in Public Relations. You can follow her on Twitter @msstaceyerin.
Posts by: Stacey
Right Turn: Blue Rodeo is aging like the rest of us
Blue Rodeo is an iconic Canadian band that performs “countrified rock” and has been around for four decades. It has received multiple awards and accolades, including being inducted into the Canadian Music Hall of Fame, and lead singers/songwriters Jim Cuddy and Greg Keelor were named Officers of the Order of Canada. I’ve been a fan […]
From the CDMO blog archives: Downstream processing
In 2019, CCRM launched a new blog to explain products, processes, terms, technologies, techniques and much more related to developing and manufacturing cell and gene therapy products. As a contract development and manufacturing organization (CDMO), CCRM wanted to share its knowledge with the global community. Fast forward to 2023 and CCRM is retiring the CDMO […]
Right Turn: Did you miss last year’s blog carnival? Don’t worry it’s back!
It’s August already. For many, this means vacation time and soaking up as much summer as possible before work and life ramp up again in the fall. For me, August means multiple family birthdays ($) and the return of the blog carnival! What is a blog carnival you ask? Signals launched its first blog carnival […]
Blog carnival: Challenges and proposed solutions to support a deluge of new CGT approvals
It’s exciting news that there are close to 2,000 advanced therapies currently in clinical trials around the world. But is it good news? It’s exciting to see how far the cell and gene therapy (CGT) industry has come and how quickly the pipeline is growing. It’s exciting that this potentially represents new treatments for patients […]